A Phase 3 interventional study of Alogliptin and Metformin HCl in Diabetes Mellitus, sponsored by Takeda. Completed at 45 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-11-28.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing alogliptin in Diabetes Mellitus — none open to participants now, none under way, none of them phase 3. alogliptin · Diabetes Mellitus.
Among the 25 studies testing alogliptin in Diabetes Mellitus, this one is the 6th largest by enrollment, is the only one that started in 2013, is one of 15 in phase 3, and was the 25th registered.
8,294 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →None of the 25 studies testing alogliptin in Diabetes Mellitus is open now. The open studies under Diabetes Mellitus, anywhere →
alogliptin: first FDA approval 2013 (NESINA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 10 · Phase 3 22
First in 2005; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 647 is above the median of 80 across 6,026 interventional studies indexed under Diabetes Mellitus.
Median enrollment 438 across the 25 interventional studies. Of the 25 that completed or were terminated, 24 (96%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 25 have an industry lead sponsor. The 1 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
71 studies in Diabetes Mellitus by Takeda: none open now, none under way, none of them phase 3. Of 71 finished, 35 (49%) have results posted.
Among the 71 studies in Diabetes Mellitus by Takeda, this one is the 12th largest by enrollment of the 66 interventional ones that give a count, is one of 3 that started in 2013, is one of 40 in phase 3, and was the 67th registered.
Takeda’s Diabetes Mellitus studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing alogliptin in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 71 in Diabetes Mellitus:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of alogliptin and metformin fixed-dose combination (FDC) as compared with alogliptin alone or metformin alone on Type 2 Diabetes Mellitus (T2DM).
The drug being tested in this study is a fixed-dose combination tablet of alogliptin and metformin to treat people who have diabetes. This study will look at glycemic control in people who take alogliptin and metformin FDC compared with alogliptin or metformin alone. The study will enroll approximately 640 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the four treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):
All participants will be asked to take 2 tablets and 1 capsule twice a day at the same time each day throughout the study. All participants will be asked to record any hypoglycemic events in a diary. This multi-center trial will be conducted in China, South Korea, Taiwan and Malaysia. The overall time to participate in this study is 34 weeks. Participants will make 11 visits to the clinic.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.
Drug: Metformin HCl · Drug: Alogliptin Placebo · Drug: Alogliptin and Metformin FDC Placebo
Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.
Drug: Alogliptin · Drug: Metformin Placebo · Drug: Alogliptin and Metformin FDC Placebo
Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.
Drug: Alogliptin and Metformin Fixed-Dose Combination (FDC) · Drug: Alogliptin Placebo · Drug: Metformin Placebo
Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.
Drug: Alogliptin Placebo · Drug: Metformin Placebo · Drug: Alogliptin and Metformin FDC Placebo
Alogliptin tablets
Also known as: SYR-322; Nesina
Metformin HCl capsules
Also known as: Glucophage
Drug pages: Alogliptin · Metformin
Alogliptin and metformin FDC tablets
Also known as: Kazano
Alogliptin placebo-matching tablets
Metformin placebo-matching capsules
Alogliptin and metformin FDC placebo-matching tablets
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (or Early Termination)
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 26 or early termination relative to baseline. Negative change indicates better glycemic control.
Time frame: Baseline and Week 26 (or Early termination)
Change From Baseline in HbA1c at Weeks 4, 8, 12, 16 and 20
The change in the value of HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Weeks 4, 8, 12, 16 and 20 relative to baseline. Negative change indicates better glycemic control.
Time frame: Baseline and Weeks 4, 8, 12, 16 and 20
Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4, 8, 12, 16, 20 and 26
The change between the FPG value collected at Weeks 4, 8, 12, 16, 20 and 26 relative to baseline. Negative change indicates better glycemic control.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26
Time to Hyperglycemic Rescue Event
Rescue is defined as meeting one of the following criteria, confirmed by a second sample drawn within 7 days of first sample: After \>1 week of treatment but prior to Week 4 visit: A single FPG ≥275 mg/dL (≥15.27 mmol/L); From the Week 4 but prior to the Week 8 visit: A single FPG ≥250 mg/dL (≥13.88 mmol/L); From the Week 8 visit but prior to the Week 12 visit: A single FPG ≥225 mg/dL (≥12.49 mmol/L); From the Week 12 visit through the end-of-treatment visit (week 26): HbA1c ≥8.5% and ≤0.5% reduction in HbA1c from baseline. Time to hyperglycemic rescue was censored if the participant did not experience a hyperglycemic rescue event.
Time frame: From the date of randomization through Week 26
Percentage of Participants Requiring Hyperglycemic Rescue
Rescue is defined as meeting one of the following criteria, confirmed by a second sample drawn within 7 days of first sample: After \>1 week of treatment but prior to Week 4 visit: A single FPG ≥275 mg/dL (≥15.27 mmol/L); From the Week 4 but prior to the Week 8 visit: A single FPG ≥250 mg/dL (≥13.88 mmol/L); From the Week 8 visit but prior to the Week 12 visit: A single FPG ≥225 mg/dL (≥12.49 mmol/L); From the Week 12 visit through the end-of-treatment visit (week 26): HbA1c ≥8.5% and ≤0.5% reduction in HbA1c from baseline.
Time frame: Baseline up to Week 26
Percentage of Participants With Marked Hyperglycemia
Marked hyperglycemia is defined as FPG level ≥200 mg/dL (11.1 mmol/L).
Time frame: Baseline up to Week 26
Change From Baseline in Body Weight at Weeks 12 and 26
Change in participant's body weight at Weeks 12 and 26 relative to baseline.
Time frame: Baseline and Weeks 12 and 26
Percentage of Participants With Glycosylated Hemoglobin ≤6.5%
Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) ≤6.5%.
Time frame: Week 26
Percentage of Participants With Glycosylated Hemoglobin ≤7.0%
Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) ≤7%.
Time frame: Week 26
Percentage of Participants With Glycosylated Hemoglobin ≤7.5%
Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) ≤7.5%.
Time frame: Week 26
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥0.5%
Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥0.5%.
Time frame: Baseline and Week 26
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥1.0%
Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥1.0%.
Time frame: Baseline and Week 26
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥1.5%
Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥1.5%.
Time frame: Baseline and Week 26
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥2.0%
Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥2.0%.
Time frame: Baseline and Week 26
Participants took part in the study at 59 investigative sites in China, Malaysia, South Korea and Taiwan from 26 August 2013 to 05 October 2015.
| Milestone | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo |
|---|---|---|---|---|
| Started | 162 | 163 | 159 | 163 |
| Treated | 161 | 162 | 159 | 163 |
| Completed | 135 | 126 | 146 | 104 |
| Not completed | 27 | 37 | 13 | 59 |
| Withdrew: Adverse event | 1 | 1 | 1 | 2 |
| Withdrew: Major protocol deviation | 3 | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 2 | 2 |
| Withdrew: Voluntary withdrawal | 8 | 8 | 2 | 11 |
| Withdrew: Lack of efficacy | 14 | 24 | 7 | 41 |
| Withdrew: Reason not specified | 0 | 1 | 1 | 2 |
| Withdrew: Randomized but not treated | 1 | 1 | 0 | 0 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 26 or early termination relative to baseline. Negative change indicates better glycemic control.
| percentage of glycosylated hemoglobin | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo |
|---|---|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (or Early Termination) | -0.32 ± 1.067 | -1.23 ± 0.877 | -1.06 ± 0.970 | -1.72 ± 1.024 |
The change in the value of HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Weeks 4, 8, 12, 16 and 20 relative to baseline. Negative change indicates better glycemic control.
| percentage of glycosylated hemoglobin | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo |
|---|---|---|---|---|
| Week 4 (n=157,156,154,156) | -0.57 ± 0.483 | -0.41 ± 0.570 | -0.80 ± 0.489 | -0.18 ± 0.503 |
| Week 8 (n=160,160,158,157) | -0.90 ± 0.682 | -0.78 ± 0.756 | -1.29 ± 0.732 | -0.29 ± 0.738 |
| Week 12 (n=160,160,158,157) | -1.06 ± 0.793 | -1.01 ± 0.839 | -1.57 ± 0.873 | -0.27 ± 0.895 |
| Week 16 (n=160,160,158,157) | -1.18 ± 0.816 | -1.06 ± 0.900 | -1.71 ± 0.937 | -0.33 ± 0.957 |
| Week 20 (n=160.160,158,157) | -1.24 ± 0.852 | -1.11 ± 0.925 | -1.74 ± 0.969 | -0.33 ± 1.006 |
The change between the FPG value collected at Weeks 4, 8, 12, 16, 20 and 26 relative to baseline. Negative change indicates better glycemic control.
| mg/dL | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo |
|---|---|---|---|---|
| Week 4 (n=157,154,155,156) | -1.42 ± 1.344 | -1.01 ± 1.794 | -2.01 ± 2.157 | 0.02 ± 1.532 |
| Week 8 (n=160,158,158,157) | -1.50 ± 1.571 | -1.17 ± 1.788 | -2.13 ± 1.808 | -0.08 ± 1.682 |
| Week 12 (n=160,158,158,157) | -1.48 ± 1.527 | -1.33 ± 1.938 | -2.14 ± 1.779 | -0.08 ± 2.112 |
| Week 16 (n=160,158,158,157) | -1.62 ± 1.599 | -1.25 ± 2.148 | -2.17 ± 1.923 | -0.07 ± 2.020 |
| Week 20 (n=160,158,158,157) | -1.57 ± 1.634 | -1.19 ± 2.248 | -2.26 ± 1.995 | -0.12 ± 2.092 |
| Week 26 (n=160,158,158,157) | -1.45 ± 1.674 | -1.06 ± 2.307 | -2.06 ± 2.274 | -0.04 ± 2.060 |
Rescue is defined as meeting one of the following criteria, confirmed by a second sample drawn within 7 days of first sample: After \>1 week of treatment but prior to Week 4 visit: A single FPG ≥275 mg/dL (≥15.27 mmol/L); From the Week 4 but prior to the Week 8 visit: A single FPG ≥250 mg/dL (≥13.88 mmol/L); From the Week 8 visit but prior to the Week 12 visit: A single FPG ≥225 mg/dL (≥12.49 mmol/L); From the Week 12 visit through the end-of-treatment visit (week 26): HbA1c ≥8.5% and ≤0.5% reduction in HbA1c from baseline. Time to hyperglycemic rescue was censored if the participant did not experience a hyperglycemic rescue event.
| days | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo |
|---|---|---|---|---|
| Time to Hyperglycemic Rescue Event | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (113.0 to NA) |
Rescue is defined as meeting one of the following criteria, confirmed by a second sample drawn within 7 days of first sample: After \>1 week of treatment but prior to Week 4 visit: A single FPG ≥275 mg/dL (≥15.27 mmol/L); From the Week 4 but prior to the Week 8 visit: A single FPG ≥250 mg/dL (≥13.88 mmol/L); From the Week 8 visit but prior to the Week 12 visit: A single FPG ≥225 mg/dL (≥12.49 mmol/L); From the Week 12 visit through the end-of-treatment visit (week 26): HbA1c ≥8.5% and ≤0.5% reduction in HbA1c from baseline.
| percentage of participants | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo |
|---|---|---|---|---|
| Percentage of Participants Requiring Hyperglycemic Rescue | 8.7 | 14.8 | 4.4 | 25.5 |
Marked hyperglycemia is defined as FPG level ≥200 mg/dL (11.1 mmol/L).
| percentage of participants | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Marked Hyperglycemia | 8.8 | 12.7 | 5.7 | 15.9 |
Change in participant's body weight at Weeks 12 and 26 relative to baseline.
| kg | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo |
|---|---|---|---|---|
| Week 12 (n=153,151,149,145) | -0.71 ± 1.735 | -0.19 ± 1.696 | -0.14 ± 1.730 | -0.32 ± 1.837 |
| Week 26 (n=156,156,156,152) | -0.93 ± 2.240 | -0.22 ± 2.291 | -0.57 ± 2.336 | -0.33 ± 2.220 |
Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) ≤6.5%.
| percentage of participants | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Glycosylated Hemoglobin ≤6.5% | 27.3 | 21.6 | 55.1 | 11.8 |
Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) ≤7%.
| percentage of participants | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Glycosylated Hemoglobin ≤7.0% | 55.9 | 44.4 | 77.2 | 30.4 |
Clinical response at Week 26 will be assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) ≤7.5%.
| percentage of participants | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Glycosylated Hemoglobin ≤7.5% | 73.3 | 60.5 | 84.8 | 46.0 |
Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥0.5%.
| percentage of participants | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo |
|---|---|---|---|---|
| Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥0.5% | 81.4 | 74.1 | 89.2 | 42.9 |
Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥1.0%.
| percentage of participants | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo |
|---|---|---|---|---|
| Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥1.0% | 63.4 | 53.7 | 83.5 | 25.5 |
Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥1.5%.
| percentage of participants | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo |
|---|---|---|---|---|
| Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥1.5% | 37.3 | 36.4 | 62.0 | 14.9 |
Clinical response at Week 26 will be assessed by the percentage of participants with a decrease from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of ≥2.0%.
| percentage of participants | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo |
|---|---|---|---|---|
| Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥2.0% | 17.4 | 17.3 | 34.8 | 6.2 |
Collected over Week 1 up to Week 28. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Metformin HCl 500 mg | — | 5/161 (3.1%) | 33/161 (20.5%) |
| Alogliptin 12.5 mg | — | 4/162 (2.5%) | 26/162 (16%) |
| Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | — | 4/158 (2.5%) | 25/158 (15.8%) |
| Placebo | — | 5/161 (3.1%) | 35/161 (21.7%) |
| Event | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo |
|---|---|---|---|---|
| Angina unstableCardiac disorders | 0/161 | 1/162 | 1/158 | 0/161 |
| Prinzmetal anginaCardiac disorders | 0/161 | 0/162 | 1/158 | 0/161 |
| Umbilical herniaGastrointestinal disorders | 0/161 | 0/162 | 1/158 | 0/161 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/161 | 0/162 | 1/158 | 0/161 |
| Bone cystMusculoskeletal and connective tissue disorders | 0/161 | 0/162 | 1/158 | 0/161 |
| Angina pectorisCardiac disorders | 0/161 | 0/162 | 0/158 | 1/161 |
| Supraventricular tachycardiaCardiac disorders | 1/161 | 0/162 | 0/158 | 0/161 |
| VertigoEar and labyrinth disorders | 1/161 | 0/162 | 0/158 | 0/161 |
| Chest discomfortGeneral disorders | 1/161 | 0/162 | 0/158 | 0/161 |
| GastroenteritisInfections and infestations | 1/161 | 0/162 | 0/158 | 1/161 |
| Event | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 11/161 | 8/162 | 8/158 | 9/161 |
| HyperlipidaemiaMetabolism and nutrition disorders | 6/161 | 9/162 | 7/158 | 10/161 |
| Protein urine presentInvestigations | 5/161 | 2/162 | 7/158 | 6/161 |
| NasopharyngitisInfections and infestations | 6/161 | 3/162 | 2/158 | 6/161 |
| DiarrhoeaGastrointestinal disorders | 5/161 | 4/162 | 1/158 | 4/161 |
Randomized set consisted of all enrolled participants who were randomized.
| Age, Continuous(years) | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 53.6 ± 9.91 | 55.4 ± 9.62 | 53.4 ± 10.46 | 52.2 ± 10.17 | 53.6 ± 10.08 |
| Sex: Female, Male(Participants) | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo | Total |
|---|---|---|---|---|---|
| Female | 80 | 65 | 68 | 68 | 281 |
| Male | 82 | 98 | 91 | 95 | 366 |
| Race/Ethnicity, Customized(participants) | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaskan Native | 0 | 1 | 0 | 2 | 3 |
| Asian | 161 | 162 | 159 | 161 | 643 |
| Multiracial | 1 | 0 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(participants) | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino (Yes) | 0 | 0 | 1 | 0 | 1 |
| Hispanic or Latino (No) | 162 | 163 | 158 | 163 | 646 |
| Height(cm) | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 163.8 ± 8.72 | 165.0 ± 8.06 | 164.3 ± 7.66 | 164.2 ± 9.19 | 164.3 ± 8.42 |
| Weight(kg) | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 70.79 ± 12.357 | 71.21 ± 11.669 | 70.73 ± 11.489 | 71.79 ± 13.949 | 71.13 ± 12.388 |
| Body Mass Index (BMI)(kg/m^2) | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 26.30 ± 3.566 | 26.16 ± 3.923 | 26.16 ± 3.508 | 26.56 ± 4.218 | 26.30 ± 3.811 |
| Smoking Classification(participants) | Metformin HCl 500 mg | Alogliptin 12.5 mg | Alogliptin 12.5 mg + Metformin HCl 500 mg FDC | Placebo | Total |
|---|---|---|---|---|---|
| Has Never Smoked | 125 | 112 | 113 | 112 | 462 |
| Is a Current Smoker | 27 | 35 | 38 | 36 | 136 |
| Is an Ex-smoker | 10 | 16 | 8 | 15 | 49 |
2 further baseline measures are reported on the registry.
The record gives a start of Sep 2013, a primary completion of Sep 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alogliptin · Metformin